Combination of anastrozole and fulvestrant extends survival in women with metastatic breast cancer
Results of a SWOG clinical trial published August 2 in the New England Journal of Medicine show the combination of anastrozole and fulvestrant extended the median survival time of women with hormone receptor-positive metastatic breast cancer by more than six months compared to women treated with a standard therapy of anastrozole alone.
Nexavar in Combination with Chemotherapy Shown to Extend Progression-Free Survival in Patients with Advanced Breast Cancer Statistically Significant Results Reported from a Phase 2 Study Combining Two Oral Cancer Therapies WAYNE, NJ and EMERYVILLE,...